EHA 2022 | Managing patients with T-ALL who relapse or are refractory to first-line treatment
Ajay Vora
• 15 Jun 2022
Ajay Vora, MD, Great Ormond Street Hospital for Children NHS Foundation Trust, London, UK, emphasizes the importance of better managing patients with T-cell acute lymphoblastic leukemia (T-ALL) who relapse or are refractory to first-line treatment. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
